

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

### **石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### **INSIDE INFORMATION**

#### **PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE HALF YEAR ENDED 30 JUNE 2023**

This announcement is made by CSPC Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

CSPC Innovation Pharmaceutical Co., Ltd. (石藥集團新諾威製藥股份有限公司) (“**CSPC XNW**”) is a subsidiary of the Company and its shares are listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765). In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC XNW published its 2023 Half Yearly Report for the half year ended 30 June 2023 on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>.

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the appendices of this announcement (the “**Appendices**”) which set out the principal financial information of CSPC XNW prepared in accordance with the PRC Accounting Standard for Business Enterprises for the half year ended 30 June 2023.

The information in the Appendices is an extract of the unaudited financial statements prepared by CSPC XNW in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 17 August 2023

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*

**APPENDIX I**

**PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS**

*Unit: RMB (Yuan)*

	Current reporting period	Corresponding reporting period of last year		Increase/decrease compared with the corresponding reporting period of last year (%)
		Before adjustment	After adjustment	After adjustment
Revenue	1,309,610,573.33	1,039,404,556.34	1,241,731,331.52	5.47%
Net profit attributable to listed company's shareholders	400,618,113.97	302,371,027.28	331,848,875.31	20.72%
Net profit attributable to listed company's shareholders less the non-recurring gain/loss	394,041,608.79	301,734,344.25	301,734,344.25	30.59%
Net cash flows from operating activities	346,366,149.89	211,307,644.94	260,450,706.29	32.99%
Basic earnings per share (Yuan/share)	0.3507	0.5538	0.3377	3.85%
Diluted earnings per share (Yuan/share)	0.3507	0.5538	0.3377	3.85%
Weighted average return on net assets	9.21%	9.74%	9.60%	-0.39%
	End of current reporting period	End of last year		Increase/decrease compared with the end of last year (%)
		Before adjustment	After adjustment	After adjustment
Total assets	5,276,732,220.61	4,584,035,512.38	4,584,035,512.38	15.11%
Net assets attributable to listed company's shareholders	4,728,544,930.43	3,935,600,634.14	3,935,600,634.14	20.15%

## APPENDIX II

### NON-RECURRING GAIN/LOSS ITEMS AND AMOUNTS

*Unit: RMB (Yuan)*

<b>Items</b>	<b>Amount</b>	<b>Description</b>
Gain/loss from disposal of non-current assets (including the part offset with the provision for impairment of assets)	61,616.98	
Government grants recognised in profit or loss of current period (excluding those closely related to the company's normal operating business and continuously granted according to certain quota of amount or volume under national policies)	7,346,740.87	
Non-operating income and expenses other than the above items	436,460.72	
Less: Impact of income tax	1,268,313.39	
Total	6,576,505.18	

## APPENDIX III

### SIGNIFICANT CHANGES IN ASSETS COMPONENTS

*Unit: RMB (Yuan)*

	End of current reporting period		End of prior year		Increase/ decrease in proportion	Description of significant changes
	Amount	Proportion to total asset	Amount	Proportion to total asset		
Bank balances and cash	2,899,821,533.76	54.95%	2,195,684,427.95	47.90%	7.05%	Mainly due to increase in bank balances and cash received by the company for goods sold and proceeds received from fund raising by the company.
Trade receivables	451,541,729.35	8.56%	481,379,233.73	10.50%	-1.94%	No significant change.
Inventories	223,913,186.35	4.24%	238,125,791.53	5.19%	-0.95%	No significant change.
Long-term equity investments	254,436,373.87	4.82%	253,488,895.12	5.53%	-0.71%	No significant change.
Fixed assets	948,183,308.56	17.97%	984,018,362.29	21.47%	-3.50%	No significant change.
Construction in progress	105,423,010.24	2.00%	70,735,076.79	1.54%	0.46%	No significant change.
Right-of-use assets	2,014,630.06	0.04%	0.00	0.00%	0.04%	No significant change.
Contract liabilities	23,884,820.41	0.45%	68,259,661.19	1.49%	-1.04%	No significant change.
Long-term borrowings	19,700,000.00	0.37%	19,800,000.00	0.43%	-0.06%	No significant change.
Lease liabilities	1,247,987.77	0.02%	0.00	0.00%	0.02%	No significant change.